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Aim: To assess the role of endogenous lactoferrin (LF) in the formation of the molecular phenotype of human breast cancer (BC) 
cell lines with varying degrees of malignancy, including cisplatin/doxorubicin resistant cell lines, and identify possible impact 
of exogenous LF. Materials and Methods: 5 breast cell lines of different origin — MCF-10 A, MCF-7, including doxorubicin/
cisplatin resistant ones, T47D, MDA-MB-231, and MDA-MB-468. Immunocytochemistry:  expression of LF, Ki-67, adhesion 
molecules E- and N-cadherin, CD44, CD24 rating the invasive potential of cells. Results: Expression of LF in human BC cell lines 
 varies. It is associated with  the heterogeneity of molecular profiles of cell lines in terms of adhesion.  A link has been established 
between the level of LF expression in the resistant cell line MCF-7/CP and MCF-7/Dox, features of their molecular profile and 
invasive properties. Exogenous LF was shown to be capable of modifying the molecular profile and invasive properties of all the 
studied cell lines including resistant ones (MCF-7/CP and MCF-7/Dox). Conclusions: The sensitivity of cytostatic-resistant cell 
lines (MCF-7/CP and MCF-7/Dox) tends to increase under the influence of exogenous LF. It is likely that this effect is due 
to LF-mediated inhibition of the expression of proteins associated with drug resistance.
Key Words: lactoferrin, cell lines of human breast cancer, molecular phenotype, proliferative activity, invasive potential, adhesion 
molecules.
INTRODUCTION
Undoubtedly, breast cancer (BC) will soon dis-
continue being a uniform nosological form as it used 
to be until recently. This is due to the fact that a vast 
majority of experts in fundamental and clinical onco-
logy have recently recognized that BC is a set of dise-
ases with different “natural evolution” and clinical 
features and that they should no longer be treated 
in a “stereotypical manner” (in particular, this ap-
plies to using chemotherapeutic agents); instead, 
tactics of individualized treatment of patients should 
be applied [1]. Such a change in the views on BC — 
a malignancy which belongs to the most common 
ones among the women population — is due to the 
fact that numerous clinical observations have proved 
the presence of distinctive associative links between 
certain morphological and functional characteristics, 
molecular-genetic profiles of tumors and clinical mani-
festations of the tumor process in BC patients [2, 3].
It has been clearly shown that the existence of inter-
tumor and intracellular heterogeneity of populations 
of malignantly transformed cells leads to a diversity 
of clinical pictures of BC and oftentimes to a failure 
to achieve a response after a standard treatment 
in individuals with similar characteristics, such as age, 
prevalence of the process, form or degree of histologi-
cal differentiation [4].
A biological phenomenon of intracellular hete-
rogeneity, which is caused by genetic instability, 
is multi-dimensional and is considered to be a key 
factor in determining the vector of the cancer process, 
both at the onset and during the realization of various 
forms of tumor progression, i.e. the aggressiveness 
of the disease [5, 6]. Many researchers believe that 
intracellular heterogeneity plays a crucial role in the 
rate of neoplasm development, its oncogenic po-
tential, and cell survival in the conditions of dynamic 
microenvironment [7–9]. The heterogeneity within the 
same tumor manifests itself in the form of differences 
between various groups of cells in terms of morpho-
logical structure, genetic and epigenetic status, as well 
as variability in the expression of various markers, 
including molecular genetic ones [10–12].
Intracellular heterogeneity makes the tumor cell 
population diverse in terms of biological potential 
of malignancy and helps it to expand by way of dis-
semination, colonization, metastasizing, and also 
enhances its resistance to antitumor effects, primarily 
to chemotherapy. There are reports showing that nu-
merous subpopulations of cells are present in a tumor 
from the very onset; they feature varying functional 
characteristics and differ in the degree of sensitivity 
or resistance to particular medicines [13, 14]. Also, 
it was established that intratumoral morphological 
heterogeneity of BC is associated with the expression 
of multidrug resistance (MDR) genes and the efficien-
cy of neoadjuvant chemotherapy (NChT). In particular, 
it was shown that tumors featuring alveolar structures 
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are characterized by a high level and up-regulation 
of main MDR genes and, at the same time, by a poor 
response to the NChT [15].
It has been proven that the parenchymatous 
component of BC with the different biological ag-
gressiveness contains cells with varying phenotypic 
and molecular genetic characteristics. Based on this, 
methods have been developed for selective thera-
peutic interventions, which should be based on the 
results of experimental studies [16, 17]. The basis for 
this are numerous reports on existing relation between 
the intratumoral morphological heterogeneity and 
the molecular subtypes in terms of expression of ER, 
PR and HER2/neu as the most intensively studied 
area of clinical molecular research in BC [18, 19]. 
In particular, it was noted that the “triple negative BC” 
more often features one single type of morphological 
structures, while luminal BC mainly features 5 types 
of structures: tubular, solid, trabecular, alveolar and 
discrete groups of tumor cells [20]. The comparison 
of the achievements of fundamental science with 
the specific characteristics of the disease course 
is an important link between the proposed hypotheses 
about the mechanisms that may underlie the disease 
development and the objective assessment of their 
likelihood in practical cancer care.
Over the last decade, along with enhanced re-
search aimed to confirm the achievements of molecu-
lar genetics concerning the existence of BC heteroge-
neity in terms of molecular phenotype, as well as their 
introduction into clinical practice, considerable efforts 
have been made to increase our knowledge about 
the role of metal-containing proteins in malignant 
transformation and tumor progression, as important 
components of metabolism, which are actively involved 
in various processes of cells’ vital activity [21]. Our 
interest is focused on fundamental research of one 
of the most poorly studied among proteins of such ori-
gin — lactoferrin (LF) [22, 23] — in terms of expression 
patterns in BC cells varying in phenotypic profile and 
malignancy degree, and the possibilities to modify the 
malignant potential of these cells when incubated with 
recombinant human LF. This interest is due to the fact 
that our own clinical observations of two geographical 
location populations of BC patients for the first time 
showed that the LF expression level is characterized 
by inter-tumor heterogeneity, as it was detected only 
in 48.0 and 53.6% of the cases, respectively. Fur-
thermore, it was proved that the survival rate among 
women with LF-positive tumors was higher than in tu-
mors of patients without LF expression [24].
Based on the above, our aim was to conduct experi-
ments in vitro to establish LF expression patterns in cell 
lines of human BC with varying malignancy potential, 
including those resistant to cisplatin and doxorubi-
cin, and to check if the phenotype of these cells can 
be modified by culturing them with exogenous LF.
MATERIALS AND METHODS
Cell lines and drug treatment. The studies were 
conducted in an in vitro system on 5 cell lines of human 
mammary of different origins: MCF-10A — immorta-
lized cells of normal human mammary; MCF-7 — in-
vasive breast ductal carcinoma; T47D — metastatic 
breast ductal carcinoma; MDA-MB-231 and MDA-
MB-468 — metastatic breast adenocarcinoma.
T47D cells were cultured in RPMI-1640 medium 
(Sigma) supplemented by bovine insulin (0.2 U/ml) 
and 10% fetal bovine serum (FBS). MCF-7 cells were 
grown in medium Dulbeccos Modified Eagles Medium 
(Sigma) supplemented by recombinant human insulin 
(0.01 mg/ml) and 10% FBS. MDA-MB-231 and MDA-
MB-468 cells were cultured in Leibovitz’s L-15 medium 
(Sigma) supplemented by 10% FBS. MCF-10A cells 
were grown in MEBM medium (Lonza) supplemented 
by cholera toxin (100 ng/ml). All cultures were grown 
on glass cover slips in humidified atmosphere with 
5% CO2 at 37 °C. The cells were provided by the Bank 
of Human and Animal Tissue Lines of the R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobiology of the National Academy of Sciences 
of Ukraine.
The resistant variants MCF-7/Dox and MCF-7/CP were 
originated by growing initial MCF-7 cells with rai sing 
concentrations of cisplatin (from 0,01 to 6 μg/ml) 
or doxorubicin (from 0.1 to 32 μg/ml), respectively. 
Cisplatin and doxorubicin were added twice a week after 
reseeding. Every 2 months, cell survival was analyzed 
by MTT assay. IC50 values for MCF-7 and MCF-7/CP cells 
were 0.25 and 1 μg/ml of cisplatin, respectively, and for 
MCF-7 and MCF-7/Dox cells — 0.5 and 8 μg/ml of doxo-
rubicin, respectively. Therefore, MCF-7/CP were 4 times 
as much resistant to the cytotoxic effect of cisplatin 
and MCF-7/DOX cells were 16 times as much resistant 
to the cytotoxic effect doxorubicin as compared with 
the initial MCF-7 cells.
MTT assay. Sensitivity to antitumor drugs (cis-
platin and doxorubicin) was measured every two 
months using standard MTT-colorimetric test with 
3-[4,5,dimethylthiasol-2–1]-2,5-diphenyltetrasolium 
bromide (“Sigma”, Germany) [25].
We used a wide range of immunocytochemical 
methods that allow establishing the molecular profile 
of malignantly transformed cells: assessment of the 
expression level of adhesion molecules such as E-cad-
herin, N-cadherin, CD44, CD24, proliferative activity 
by expression of Ki-67. The LF expression in tumor cells 
and their invasive properties were studied. Cells for im-
munocytochemical studies were grown on glass cover 
slips, fixed in cooled mixture of methanol:acetone (1:1) 
at −-20 °C for 120 min, washed in PBS and incubated 
with 1% BSA for 20 min. Primary monoclonal antibod-
ies: anti-lactoferrin (ThermoScientific, USA); anti-
Кi-67 (DakoCytomation, Denmark); anti-CD24 (Neo-
Markers, USA); anti-CD44 (Diagnostic BioSystems, 
USA); anti-E-cadherin (ThermoScientific, USA), 
anti-CD325 ( N-Cadherin) (DakoCytomation, Denmark) 
were diluted in the blocking buffer and kept at a room 
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temperature for one hour, followed by incubation with 
UltraVision LP Detection System (Lab Vision, Thermo 
Scientific) for 10 and 15 min; after the washing, the 
immune reaction was visualized by using DAB Quanto 
(Thermo Scientific). When immunocytochemical re-
actions were completed, the cells were stained with 
hematoxylin by Mayer for 10–15 s and placed in Fara-
mount Aqueous Mounting Medium (DakoCytomation, 
Denmark). Evaluation of the results was carried out 
in 3 visual fields by light microscopy (x1000, oil immer-
sion) using the classical H-Score method: 
S = 1×N1+ + 2×N2+ + 3×N3+, 
where S is “H-Score” index, N1+, N2+ and N3+ are num-
bers of cells with low, medium or high levels of marker 
expression.
It should be noted that in previous studies we have 
identified biomolecular markers that characterize the 
metastatic potential and invasive activity of BC cells 
of abovementioned lines [18].
Invasive activity. The invasive activity was inves-
tigated using a standard method, according to manu-
facturer’s recommendations (BD Biosciences). For 
this purpose, the matrigel membranes (BD BioCoat™ 
Matrigel™ Invasion Chamber, Bedford, MA) with pore 
sizes of 8 microns were used. In the upper part of the 
membrane, the cell suspension was placed in a con-
centration of 5•104 cells/well in culture medium without 
the addition of bovine serum. In the lower part, the 
standard culture medium supplemented with 10% FBS 
was introduced. The cells were then incubated under 
standard conditions at temperature of 37 °C in hu-
midified atmosphere with 5% CO2 during 48 hours. 
The membranes were then fixed with methanol, fol-
lowed by staining with crystal violet B. The number 
of cells on outside of membrane was evaluated using 
light microscopy (×100, oil immersion).
LF preparation (obtaining). Milk of goats trans-
fected with human LF gene (joint development of SPC 
on Livestock Farming of the National Academy of Sci-
ences of Belarus and the Institute of Gene Biology, Rus-
sian Academy of Sciences) was subjected to the stan-
dard procedure of casein removing. Chromatography 
was performed using a medium pressure liquid chro-
matograph ACTAFPLCsystem (Amersham-Pharmacia). 
Milk serum was applied to a HiPrep 16/10 SP HL column 
(Amersham-Pharmacia) that was prewashed with 
equilibration buffer (20 mМ phosphate Na; 0.4 М NaCl; 
рН 6.5) at a rate 1 ml/min. LF was eluted with a linear 
gradient 0.4 М — 1 М NaCl. Fractions containing 
LF were concentrated and desalted using ultrafiltra-
tion cassettes Vivaflow 50 (Sartorius) with a molecular 
weight cut-off of 30 kDa. The resulting concentrate was 
lyophilized on Lyophilize ALPHA 1–4 LDplus. The purity 
of obtained LF (> 99%) was assessed by denaturing gel 
electrophoresis in polyacrylamide gel in the presence 
of sodium dodecyl sulfate.
Recombinant human LF, which was used in ex-
periments in vitro, was diluted in PBS and added di-
rectly to the culture medium at a final concentration 
of 100 μg/mL. Cells were cultured with LF during 72 h.
Statistical analysis  was performed with 
 STATISTICA 6.0 software (StatSoft Inc., USA). The all 
data were obtained in triplicate experiments. The va-
lues were expressed as means ± standard deviation 
(SD). Student’s t-test was used to evaluate the sig-
nificance of the differences between groups. A value 
of p < 0.05 was accepted as statistically significant.
RESULTS AND DISCUSSION
Immunocytochemical determination of LF revealed 
that this metal-containing protein shows varying ex-
pression levels in the tested BC cell lines (Table 1). 
The highest LF expression was observed in cell lines 
T47D and MCF-7 that possess low invasive activity, 
which according to the molecular phenotype is caused 
by the increased adhesion properties of these cells 
due to the high expression level of E-cadherin and low 
expression level of CD44, in the absence of CD24 ex-
pression. Levels of N-cadherin expression were defi-
nitely moderate.
The lowest level of LF expression was seen in cell line 
MDA-MB-468, that is characterized by the highest rates 
of invasion activity, which according to their molecular 
profile is explained by the higher expression of adhe-
sion molecules CD44 and CD24 as compared with 
those in cell lines T47D and MCF-7 with a low invasive 
potential. At the same time, expression of E-cadherin 
has been at the values range typical for cells with 
a low invasion activity. Levels of the LF expression 
were slightly higher in cell line MDA-MB-231, which 
by its invasive properties were inferior to cell line MDA-
MB-468, and among the tested cell lines had the lowest 
level of E-cadherin expression, the highest expression 
of CD44 molecules and the positive response to CD24.
Table 1. Changes in the molecular profile of BC cells with different molecular phenotype and invasive properties caused by cultivation with LF
Cell lines Level of LF expression Cells’ proliferative activity CD24 CD44 Е-cadherin N-cadherin Invasion, ×103 cells
T47D 285.0 ± 2.1 89.0 ± 1.4 0 79.0 ± 3.1 251.0 ± 5.0 53.0 ± 2.4 0.081 ± 0.002
T47D + LF − 63.0 ± 0.8* 0 43.0 ± 1.1* 263.0 ± 3.2* 49.0 ± 2.0 0.061 ± 0.005*
MCF-7 251.0 ± 2.3 291.0 ± 2.4 0 72.0 ± 2.8 268.0 ± 4.6 59.0 ± 1.6 0.087 ± 0.005
MCF-7 + LF − 170.0 ± 2.1* 0 32.0 ± 2.3* 283.0 ± 3.6* 56.0 ± 1.9 0.070 ± 0.004
MDA-MB-231 92.0 ± 1.9 268.0 ± 1.9 34.0 ± 2.6 298.0 ± 0.7 49.0 ± 1.3 31.0 ± 0.7 0.192 ± 0.021
MDA-MB-231 + LF − 130.0 ± 2.3* 34.0 ± 2.6 164.0 ± 1.7* 148.0 ± 2.9* 48.0 ± 0.9* 0.153 ± 0.014*
MDA-MB4–68 70.0 ± 1.6 249.0 ± 2.7 153.0 ± 4.0 167.0 ± 5.0 259.0 ± 2.5 18.0 ± 0.8 0.340 ± 0.011
MDA-MB-468 + LF − 119.0 ± 2.8* 110.0 ± 2.1* 96.0 ± 3.0* 293.0 ± 2.8* 31.0 ± 0.9* 0.190 ± 0.021*
MCF-10A 157.0 ± 1.8 191.0 ± 2.3 63.0 ± 1.8 174.0 ± 4.3 149.0 ± 1.1 31.0 ± 1.6 0.240 ± 0.016
MCF-10A + LF − 130.0 ± 2.7* 42.0 ± 1.6* 110.0 ± 2.3* 189.0 ± 1.9* 28.0 ± 1.1* 0.176 ± 0.009
MCF-7/CP 105.0 ± 1.7 143.0 ± 2.5 0 176.0 ± 2.1 57.0 ± 1.9 179.0 ± 1.7 0.280 ± 0.010
MCF-7/CP + LF 0 87.0 ± 1.5* 0 98.0 ± 2.2* 115.0 ± 1.6* 143.0 ± 1.8** 0.154 ± 0.013*
MCF-7/Dox 67.0 ± 1.9 95.0 ± 1.8 0 234.0 ± 2.3 28.0 ± 2.3 238.0 ± 1.9 0.352 ± 0.022
MCF-7/Dox + LF 0 62.0 ± 1.6* 0 110.0 ± 2.3* 73.0 ± 1.9* 169.0 ± 1.8* 0.142 ± 0.008*
Note: *p < 0.05 compared with cell lines without LF.
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In immortalized cells of human mammary cell line 
MCF-10A without signs of malignant transformation, 
we found a high LF expression. By its invasive proper-
ties the cells of that line occupied intermediate position 
between cell lines MDA-MB-468 and MDA-MB-231. 
In these cells, there was a high level of CD44 and 
CD24 expression and, at the same time, a fairly high ex-
pression of E-cadherin (see Table 1). It should be noted 
that the proliferative activity was equally high in the 
tested cell lines and did not significantly affect both the 
levels of the LF expression and invasive activity. Thus, 
according to our findings, the level of LF expression 
in human BC cell lines of different origins is associated 
with their invasive properties. At the same time, the 
invasive activity of the tested cell lines is caused by the 
expression of various adhesion molecules: the weak 
manifestations of invasion associates with the high level 
of E-cadherin expression and the lack of CD24 expres-
sion, while cells with an active invasion showed a shift 
towards increased expression levels of CD44 and CD24. 
The above mentioned differences are the direct evi-
dence of interlinear heterogeneity of BC cells in both the 
level of LF expression and the molecular profile which 
determines their invasive properties.
Along with this, we evaluated the features of LF ex-
pression in cells of the two resistant BC lines, namely 
cisplatin-resistant (MCF-7/CP), and doxorubicin-
resistant (MCF-7/Dox) (see Table 1). According to our 
findings, the LF expression level in cell line MCF-7/
CP was much higher than that in cell line MCF-7/
Dox. At the same time, invasive activity was more 
pronounced in cell line MCF-7/Dox, which was cha-
racterized by a low expression of this metal-containing 
protein. In both lines, we found low levels of E-cadherin 
expression, which were significantly lower in cell line 
MCF-7/Dox; high expression levels of CD44 and 
 N-cadherin, significantly higher in cells resistant 
to doxorubicin; and absence of CD24 expression 
in both cell lines. The proliferative activity was lower 
in cell line MCF-7/Dox.
In the literature, there are data obtained in vivo and 
in vitro systems, which show that exogenous LF can 
affect the rate of tumor cells growth. Thus, in vivo 
experiments showed that systemic effects of LF re-
sulted in the inhibited growth of squamous cell skin 
carcinoma transplanted to normal mice; while when 
the tumor was transplanted into immune-deficient 
mice such effect was absent. The same tendency was 
seen when metastatic colon cancer was transplanted 
to normal mice and athymic animals [25]. In animals 
with subcutaneously transplanted highly metastatic 
colon carcinoma, the number of lung metastases de-
creased by 48.0% after LF administration. In the same 
model, it was shown that the reduction of the metas-
tasis intensity was accompanied by the increased In-
terleukin 18 production and the subsequent induction 
of interferon, to which the authors attribute the anti-
metastatic effect of LF. In addition, the resear chers 
concluded that the activation of Interleukin 18 was 
associated with the activation of caspase 1 [26]. Using 
small angle X-ray scattering, light scattering and abla-
tion, it was convincingly shown that DNA, nucleotides 
and oligosaccharides cause the formation of certain 
LF oligomers, which differ in their antitumor activities 
and influence on the immune system [27]. Finally, 
in studies on clinical material received from patients 
with intestinal polyposis it has been found that a long-
term LF administration in high doses was not toxic 
and resulted in slower growth of polyps. The studies 
have shown that after the action of digestive enzymes 
the LF cleaves forming lactoferritin which retains the 
biological activity of LF. In experiments conducted 
on cell cultures aiming to determine the mechanisms 
of LF action, it was shown that in some types of tu-
mor cells LF is capable of stimulating apoptosis and 
inhi biting cell proliferation by blocking the transition 
from G1 phase to S phase of the cell cycle [28, 29]. 
At the same time, in one of the reports it was noticed 
that in human BC cell line MCF-7 LF did not inhibit 
the tumor cell growth if it was cultured with this iron-
containing protein [30].
A scarce and controversial data on this issue have 
prompted us to analyze whether LF really has a modi-
fying effect on the molecular profile and invasive 
properties of tested BC cell lines by culturing them with 
exogenous LF (see Table 1). As a result of this phase 
of research, it was found that culturing all tested human 
BC cell lines with LF resulted in the decrease of their 
malignant potential, but the manifestations of the ac-
tion of the iron-containing protein were ambiguous. 
In particular, there was a decline in proliferative activity 
levels and a significant weakening of the cells’ invasive 
properties due to enhanced intercellular adhesion (sig-
nificant increase in the E-cadherin expression and de-
crease in the CD44 expression). The CD24 expression 
was slightly reduced, and the expression of N-cadherin 
did not change substantially. It should be noted that the 
most pronounced effects of changes in the molecular 
profile and invasive properties under the LF influence 
were observed in the BC cell lines MDA-MB-231 and 
MDA-MB-468, which had the  highest malignant po-
tential according to the investigated parameters that 
was identified before incubating the cells with this 
iron-containing protein.
Analysis of the biological effect of LF on the mo-
lecular profile of cytostatic-resistant BC cells that 
characterizes their adhesive properties and invasive 
activity, allowed us identifying a number of common 
features and essential peculiarities in each of the 
tested lines. Thus, a common feature for both resistant 
lines exposed to LF was a significant inhibition of proli-
feration activity, decrease of the E-cadherin expression 
level, significant decline of CD44 expression, as well 
as reduction of N-cadherin expression. Directly in cell 
line MCF-7/CP, the level of E-cadherin expression 
increased twice. The CD44 expression decreased 
by 1.7 times, as well as the index of their invasive ac-
tivity. In cell line MCF-7/Dox these indices changed 
even more dramatically: the expression of E-cadherin 
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increased twice, the expression of CD44 and invasive 
activity decreased by 2.5 times.
The obtained data became the basis for the study 
of the LF impacts on the most important component 
of molecular phenotype of resistant cells — expression 
of proteins associated with MDR: namely P-gp and 
GST. Immunohistochemical studies showed that 
in cell line MCF-7/CP, which was not subjected to the 
LF influence, P-gp expression was not detected, and 
the GST expression level was 276.0 ± 2.2 (Table 2). 
In cell line MCF-7/Dox, which also served as the 
similar control, on the contrary, the P-gp expression 
was determined (285.0 ± 1.9), while there was no ex-
pression of GST. Culturing the cells of both lines with 
LF caused a substantial reduction of expression of the 
tested proteins: GST halved in cell line MCF-7/CP and 
P-gp halved in cell line MCF-7/Dox.
Table 2. The changes in expression of proteins associated with drug re-
sistance in BC cells with the phenotype of drug resistance caused by cul-
tivating with LF
Resistance 
marker
Cell line
MCF-7/CP MCF-7/СР + LF MCF-7/Dox MCF-7/Dox + LF
P-gp 0 0 285.0 ± 1.9 120.0 ± 1.6*
GST 276.0 ± 2.2 135.0 ± 2.4* 0 0
Note: *p < 0.03 compared with cell line without LF.
The next step in the identification of the LF influ-
ence on cytostatic-resistant MCF-7 cell line was the 
study of the ability of this iron-containing protein 
to increase cells’ sensitivity to anticancer drugs. Our 
findings showed that the doxorubicin IC50 for cell line 
MCF-7/Dox after incubation with LF increased twice 
as compared with the cells of that line not exposed 
to LF, indicating a substantial increase in their sensiti-
vity to this cytostatic (Table 3). A similar phenomenon 
of increasing the cells’ sensitivity caused by their 
culturing with LF was found in cell line MCF-7/CP to-
wards cisplatin too. Less pronounced manifestations 
of cells sensitivity enhancement to cytostatics in terms 
of IC50 were noticed in cell line MCF-7/Dox towards 
cisplatin and in MCF-7/CP towards doxorubicin. Thus, 
the contact of LF with cell lines MCF-7, which is re-
sistant, among others, to doxorubicin and cisplatin, 
is able of significantly improving their sensitivity to the 
above-mentioned cytostatics.
Table 3. Increased sensitivity of BC cells to anticancer drugs caused by cul-
tivation with LF
Antican-
cer drug
IC50, µgM
Cell line
MCF-7 MCF-7 + LF
MCF-7/
Dox
MCF-7/
Dox + LF
MCF-7/
СР
MCF-7/
СР + LF
Doxoru-
bicin
4.1±0.3 3.5±0.2* 23.3±2.1 12.0±0.6* 12.4±1.2 9.3±0.4*
Cisplatin 15.3±1.3 12.9±0.3* 16.0±1.0 13.0±0.4* 93.3±7.0 54.8±0.7*
Note: *p < 0.05 compared with cell line without LF.
Our findings do not contradict the results of other 
studies that evidence that the manifestation of LF ef-
fects on some properties of tumor cells in vitro can 
be regarded as anti-carcinogenic effect [31]. The above 
gives hope for the future prospects of the prescription 
of LF in the complex personalized therapy of BC pa-
tients. At the same time, our own experimental studies 
indicate that, at the stage of establishing BC diagnosis, 
it is needed to conduct, along with the LF expression 
evaluation, also the assessment of certain molecular 
markers’ expression, which can help identify the ma-
lignant potential of the neoplasm, and on this basis 
to focus on the individualized prescription of LF.
The fact that LF in vitro has the ability of increasing 
tumor cells’ sensitivity to cytostatics, especially resis-
tant ones, warrants further studies using exogenous 
LF in vivo to confirm the effect of overcoming MDR.
A significant obstacle to large-scale research and 
multi-center clinical trials is the absence of recombi-
nant human LF in the international market. At present, 
the developments of genetically engineered con-
structs with gene of human LF are being carried out 
actively for production of this protein on a commercial 
scale [32, 33]. The successful resolution of this issue 
will help approach the time when the use of LF in the 
complex treatment of BC patients will become a reality.
CONCLUSIONS
1. It was shown that the tested human BC cell lines 
are heterogeneous in terms of LF expression.
2. The various manifestations of LF expression 
in the tested human BC cell lines are associated with 
the heterogeneity of molecular profile of these cell 
lines in terms of adhesion.
3. The highest level of the LF expression was ob-
served in cell lines T47D and MCF-7, which have the 
lowest manifestations of invasive properties. Cell lines 
MDA-MB-231 and MDA-MB-468 with highly invasive 
activities feature low levels of the LF expression.
4. The relationship between the LF expression le-
vels in resistant cell lines MCF-7/CP and MCF-7/Dox 
and the features of their molecular profile and invasive 
properties was established.
5. The modifying effect of LF on the molecular 
profile and invasive properties of all tested lines, in-
cluding resistant ones — MCF-7/CP and MCF-7/Dox, 
was established.
6. The inhibitory effect of LF on the expression 
of proteins associated with MDR was established 
in BC cells with MDR phenotypes.
7. As a result of the cultivation with LF of initial human 
BC cell lines and BC cell lines resistant to cytostatics, 
their sensitivity to doxorubicin and cisplatin increased, 
which was most pronounced in the resistant cell lines: 
MCF-7/CP and MCF-7/Dox. This effect is due to the 
inhibited expression of MDR associated proteins.
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